Mirador Capital Partners LP Boosts Stock Holdings in Celldex Therapeutics, Inc. $CLDX

Mirador Capital Partners LP grew its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 24.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 158,717 shares of the biopharmaceutical company’s stock after buying an additional 30,843 shares during the quarter. Mirador Capital Partners LP owned 0.24% of Celldex Therapeutics worth $3,230,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. PDT Partners LLC purchased a new stake in Celldex Therapeutics during the 1st quarter valued at $379,000. Trexquant Investment LP purchased a new stake in shares of Celldex Therapeutics during the first quarter valued at $1,420,000. Deutsche Bank AG boosted its position in shares of Celldex Therapeutics by 13.8% during the first quarter. Deutsche Bank AG now owns 138,289 shares of the biopharmaceutical company’s stock valued at $2,510,000 after buying an additional 16,788 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Celldex Therapeutics during the fourth quarter valued at $835,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Celldex Therapeutics during the 1st quarter valued at about $1,131,000.

Celldex Therapeutics Stock Up 0.3%

Shares of Celldex Therapeutics stock opened at $24.58 on Wednesday. The stock’s 50-day simple moving average is $22.89 and its 200-day simple moving average is $20.79. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -8.17 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.13 million. On average, equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CLDX shares. HC Wainwright dropped their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. Wells Fargo & Company dropped their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a report on Wednesday, August 20th. Citigroup dropped their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. Finally, Canaccord Genuity Group dropped their price target on Celldex Therapeutics from $64.00 to $62.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $46.67.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.